A mystery Moderna asset hits the clinic
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
Otsuka zips into adjuvant use
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
More conjugates pile into the clinic
J&J, Astra, Pfizer and others move yet more ADCs into human studies.
CatalYm joins Pfizer in pivotal cachexia push
Shortly after ponsegromab, visugromab is to start phase 2/3.
Novita goes into phase 3
Meanwhile, ASK Pharm challenges Hutchmed in cMet.
ALX's conjugate foray goes clinical
ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
Bristol takes its bispecific conjugate into lung cancer
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
